美股詳情

本頁面由Tiger Trade Technology Pte. Ltd.提供服務

Zenas BioPharma Inc.

18.21

-3.9500-17.82%

盤後：18.350.1400+0.77%19:39 EDT

成交量：336.71萬

成交額：6,111.13萬

市值：10.45億

市盈率：-2.16

高：19.35

開：19.23

低：17.20

收：22.16

52周最高：44.60

52周最低：6.11

股本：5,737.10萬

流通股本：3,164.18萬

量比：3.16

換手率：10.64%

股息：- -

股息率：- -

每股收益(TTM):-8.4400

每股收益(LYR):-8.4448

淨資產收益率：-136.22%

總資產收益率：-35.06%

市淨率：4.31

市盈率(LYR):-2.16

資料載入中...

總覽公司新聞資訊公告

BUZZ--美國股票走勢-Entergy 公司、IDEX 公司、廣達服務公司

BUZZ--美國股票走勢-Entergy 公司、IDEX 公司、廣達服務公司

Zenas BioPharma完成3億美元融資：發行可轉債與普通股，加速自免藥物開發

BUZZ-Zenas 生物製藥公司因發行可轉換債券和股票而下跌

Zenas BioPharma Inc. 融資收益將用於支持Obexelimab美國上市、管線推進及一般企業用途

Zenas BioPharma宣佈擬同步公開發行2032年到期可轉換優先票據及普通股

Zenas BioPharma 公布2025年第四季度及全年財務業績並更新公司進展

Zenas BioPharma公布Obexelimab治療複發性多發性硬化症的2期Moonstone試驗結果，將於2026年Actrims論壇進行突破性平台展示

Zenas Biopharma, Inc.盤中異動股價大漲5.14%

Zenas Biopharma, Inc.盤中異動股價大漲5.12%報19.08美元

Zenas Biopharma, Inc.盤中異動早盤急速下挫5.12%

美國研究綜述-不倫瑞克、派克-漢尼汾、XPLR 基礎設施

Zenas BioPharma股價因免疫疾病藥物後期數據不佳而跌至逾四個月低點，日內跌幅達55%

Zenas 生物製藥公司的免疫紊亂藥物在後期試驗中達到主要目標

Zenas BioPharma公布Obexelimab治療IgG4相關疾病3期INDIGO註冊試驗積極結果

InnoCare Pharma宣佈Orelabrutinib（Btk抑制劑）在系統性紅斑狼瘡的2B期研究中實現主要終點

Zenas BioPharma：Obexelimab三期Indigo試驗在免疫球蛋白G4相關疾病（IgG4-RD）中的初步結果預計將在年末公布

Zenas Biopharma公布Obexelimab在複發性多發性硬化症II期Moonstone試驗中取得積極結果

Zenas Biopharma預計將在2026年第一季度啓動Orelabrutinib針對繼發漸進性多發性硬化症患者的全球三級臨床試驗

Zenas Biopharma向SEC申請最多出售630萬股普通股的架構籌資

{"basename":"/hant","ssrTDKData":{"titleTemplate":"%s - 老虎證券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎證券,老虎證券開戶,老虎券商,老虎證券官網,老虎證券app,tigertrade老虎證券,股票,炒股,新加坡股票交易平臺,投資,投資理財","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/hant/stock/ZBIO/news"},"companyName":"老虎證券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental","symbol":"ZBIO","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"ZBIO\",,,,,undefined,":{"symbol":"ZBIO","market":"US","secType":"STK","nameCN":"Zenas BioPharma Inc.","latestPrice":18.21,"timestamp":1774641600000,"preClose":22.16,"halted":0,"volume":3367077,"hourTrading":{"tag":"盘后","latestPrice":18.35,"preClose":18.21,"latestTime":"19:39 EDT","volume":3933,"amount":72004.1236,"timestamp":1774654773438,"change":0.14,"changeRate":0.007688,"amplitude":0.035815},"delay":0,"changeRate":-0.17824909747292417,"floatShares":31641800,"shares":57371044,"eps":-8.44,"marketStatus":"休市中","change":-3.95,"latestTime":"03-27 16:00:00 EDT","open":19.225,"high":19.35,"low":17.2,"amount":61111282.54135801,"amplitude":0.097022,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":0,"etf":0,"ttmEps":-8.44,"tradingStatus":0,"nextMarketStatus":{"tag":"盤前交易","tradingStatus":1,"beginTime":1774857600000},"marketStatusCode":7,"adr":0,"adrRate":0,"listingDate":1726200000000,"exchange":"NASDAQ","adjPreClose":22.16,"sharesOutstanding":249967,"nav":10.0592,"aum":2514468.0464,"bidAskSpread":0,"preHourTrading":{"tag":"盘前","latestPrice":19.32,"preClose":22.16,"latestTime":"09:29 EDT","volume":32153,"amount":619695.7653259999,"timestamp":1774618189486,"change":-2.84,"changeRate":-0.128159,"amplitude":0.068285},"postHourTrading":{"tag":"盘后","latestPrice":18.35,"preClose":18.21,"latestTime":"19:39 EDT","volume":3933,"amount":72004.1236,"timestamp":1774654773438,"change":0.14,"changeRate":0.007688,"amplitude":0.035815},"volumeRatio":3.158856,"impliedVol":0.7765,"impliedVolPercentile":0.2674},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"ZBIO\",,,,,undefined,":{"symbol":"ZBIO","floatShares":31641800,"roa":"-35.06%","roe":"-136.22%","lyrEps":-8.444814,"volumeRatio":3.158856,"shares":57371044,"dividePrice":0,"high":19.35,"amplitude":0.097022,"preClose":22.16,"low":17.2,"week52Low":6.11,"pbRate":"4.31","psRate":"104.47","week52High":44.6,"institutionHeld":0,"latestPrice":18.21,"eps":-8.44,"divideRate":0,"volume":3367077,"delay":0,"ttmEps":-8.44,"open":19.225,"prevYearClose":36.31,"prevWeekClose":22.3,"prevMonthClose":26.35,"prevQuarterClose":36.31,"fiveDayClose":22.3,"twentyDayClose":26.35,"sixtyDayClose":36.58},"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/ZBIO\",params:#limit:5,,,undefined,":[{"market":"US","date":"2026-03-16","symbol":"ZBIO","fiscalQuarterEnding":"2025/12","expectedEps":-1.22,"name":null,"time":"盤前","type":"earning","dateTimestamp":1773633600000,"reportTimeType":"pre","actualEps":-4.54},{"market":"US","date":"2025-11-12","symbol":"ZBIO","fiscalQuarterEnding":"2025/09","expectedEps":-0.87,"name":null,"time":"盤前","type":"earning","dateTimestamp":1762923600000,"reportTimeType":"pre","actualEps":-1.22},{"market":"US","date":"2025-08-12","symbol":"ZBIO","fiscalQuarterEnding":"2025/06","expectedEps":-1.02,"name":null,"time":"盤前","type":"earning","dateTimestamp":1754971200000,"reportTimeType":"pre","actualEps":-1.25},{"market":"US","date":"2025-05-15","symbol":"ZBIO","fiscalQuarterEnding":"2025/03","expectedEps":-1.15,"name":null,"time":"盤前","type":"earning","dateTimestamp":1747281600000,"reportTimeType":"pre","actualEps":-0.8},{"market":"US","date":"2024-11-12","symbol":"ZBIO","fiscalQuarterEnding":"2024/09","expectedEps":13,"name":null,"time":"盤前","type":"earning","dateTimestamp":1731387600000,"reportTimeType":"pre","actualEps":-5.02}],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"ZBIO\",market:\"US\",,,undefined,":[],"@#url:\"https://hq.skytigris.cn/fundamental/estimate/recommendation\",params:#symbol:\"ZBIO\",market:\"US\",delay:false,,,undefined,":{"strongBuy":0.625,"buy":0.25,"hold":0.125,"sell":0,"strongSell":0,"meanLabel":"STRONG BUY","meanPercent":0.625,"analysts":8,"updateTime":1767758400000},"@#url:\"https://hq.skytigris.cn/value_analysis/stock/ZBIO\",params:#withQuantilePoint:true,period:\"5year\",factor:\"peRate\",delay:false,algorithm:1,,,undefined,":{"brief":{"id":"ZBIO","date":"2026-03-26","current":-2.157583,"percent":0.603133,"low":-19.592941,"twenty":-9.777499,"median":-4.036629,"eighty":-2.541078,"high":-1.802568,"avg":-5.781385,"sd":4.047568,"marketCap":1273063466},"quantilePoints":[{"date":"2024-09-13","current":-8.364044,"twenty":-11.189626,"median":-10.130033,"eighty":-9.07044,"marketCap":457989962},{"date":"2024-09-20","current":-12.731934,"twenty":-12.968841,"median":-12.731934,"eighty":-9.523082,"marketCap":697162515},{"date":"2024-09-27","current":-12.564791,"twenty":-13.484804,"median":-12.909978,"eighty":-12.029776,"marketCap":688010267},{"date":"2024-10-04","current":-14.275075,"twenty":-13.747873,"median":-12.811872,"eighty":-12.31335,"marketCap":781660299},{"date":"2024-10-11","current":-13.008553,"twenty":-13.941177,"median":-13.027627,"eighty":-12.397648,"marketCap":712309358},{"date":"2024-10-18","current":-16.373229,"twenty":-14.273549,"median":-13.29848,"eighty":-12.477586,"marketCap":896548905},{"date":"2024-10-25","current":-17.845752,"twenty":-15.022781,"median":-13.503182,"eighty":-12.59822,"marketCap":977179818},{"date":"2024-10-31","current":-16.022265,"twenty":-16.022265,"median":-13.891034,"eighty":-12.731934,"marketCap":877331175},{"date":"2024-11-08","current":-15.961228,"twenty":-15.961228,"median":-14.267446,"eighty":-12.811872,"marketCap":873988961},{"date":"2024-11-15","current":-6.06727,"twenty":-16.022265,"median":-14.202594,"eighty":-12.564791,"marketCap":782495852},{"date":"2024-11-22","current":-3.382919,"twenty":-15.961228,"median":-13.807463,"eighty":-11.896022,"marketCap":436298426},{"date":"2024-11-29","current":-3.729636,"twenty":-15.955124,"median":-13.496851,"eighty":-6.578437,"marketCap":481014835},{"date":"2024-12-06","current":-3.402361,"twenty":-15.898664,"median":-13.178717,"eighty":-4.851473,"marketCap":438805888},{"date":"2024-12-13","current":-2.997318,"twenty":-15.744546,"median":-13.008553,"eighty":-3.729636,"marketCap":386567092},{"date":"2024-12-20","current":-3.162575,"twenty":-15.636205,"median":-12.771903,"eighty":-3.606503,"marketCap":407880521},{"date":"2024-12-27","current":-3.256545,"twenty":-15.585849,"median":-12.510288,"eighty":-3.394584,"marketCap":419999921},{"date":"2025-01-03","current":-2.91955,"twenty":-15.427152,"median":-12.339512,"eighty":-3.24488,"marketCap":376537243},{"date":"2025-01-10","current":-3.007039,"twenty":-15.189107,"median":-10.412935,"eighty":-3.188498,"marketCap":387820823},{"date":"2025-01-17","current":-2.520987,"twenty":-15.022781,"median":-6.676265,"eighty":-3.159983,"marketCap":325134267},{"date":"2025-01-24","current":-2.715408,"twenty":-14.870188,"median":-6.06727,"eighty":-3.071846,"marketCap":350208890},{"date":"2025-01-31","current":-2.469142,"twenty":-14.351372,"median":-4.794107,"eighty":-2.968155,"marketCap":318447701},{"date":"2025-02-07","current":-2.54367,"twenty":-14.313224,"median":-3.888412,"eighty":-2.841781,"marketCap":328059640},{"date":"2025-02-14","current":-2.313605,"twenty":-14.275075,"median":-3.716674,"eighty":-2.653842,"marketCap":298388004},{"date":"2025-02-21","current":-2.530708,"twenty":-14.268972,"median":-3.643766,"eighty":-2.622086,"marketCap":326387998},{"date":"2025-02-28","current":-2.141867,"twenty":-14.163683,"median":-3.476889,"eighty":-2.54367,"marketCap":276238754},{"date":"2025-03-07","current":-2.35573,"twenty":-14.007233,"median":-3.332693,"eighty":-2.517747,"marketCap":303820838},{"date":"2025-03-14","current":-2.324434,"twenty":-13.840892,"median":-3.246824,"eighty":-2.465902,"marketCap":364908203},{"date":"2025-03-21","current":-2.26852,"twenty":-13.569102,"median":-3.188498,"eighty":-2.360915,"marketCap":356130342},{"date":"2025-03-28","current":-2.138053,"twenty":-13.499383,"median":-3.165816,"eighty":-2.351842,"marketCap":335648668},{"date":"2025-04-04","current":-2.076814,"twenty":-13.408148,"median":-3.159335,"eighty":-2.284767,"marketCap":326034820},{"date":"2025-04-11","current":-1.80523,"twenty":-13.315978,"median":-3.071846,"eighty":-2.26652,"marketCap":283399498},{"date":"2025-04-17","current":-2.21793,"twenty":-13.154764,"median":-2.997318,"eighty":-2.257224,"marketCap":348188468},{"date":"2025-04-25","current":-2.657256,"twenty":-13.051602,"median":-2.943853,"eighty":-2.261324,"marketCap":417157373},{"date":"2025-05-02","current":-3.077944,"twenty":-13.023813,"median":-2.968155,"eighty":-2.26639,"marketCap":483200324},{"date":"2025-05-09","current":-2.4756,"twenty":-13.008271,"median":-2.943853,"eighty":-2.269325,"marketCap":388639550},{"date":"2025-05-16","current":-2.503456,"twenty":-12.890356,"median":-2.890387,"eighty":-2.270833,"marketCap":407464932},{"date":"2025-05-23","current":-2.942974,"twenty":-12.763909,"median":-2.866084,"eighty":-2.272453,"marketCap":479001383},{"date":"2025-05-30","current":-2.570283,"twenty":-12.665077,"median":-2.835832,"eighty":-2.278934,"marketCap":418341820},{"date":"2025-06-06","current":-2.470042,"twenty":-12.521189,"median":-2.721889,"eighty":-2.297829,"marketCap":402026489},{"date":"2025-06-13","current":-2.90956,"twenty":-12.426717,"median":-2.835832,"eighty":-2.31327,"marketCap":473562940},{"date":"2025-06-20","current":-2.392933,"twenty":-12.365673,"median":-2.76689,"eighty":-2.315238,"marketCap":389476234},{"date":"2025-06-27","current":-2.608837,"twenty":-12.215932,"median":-2.714219,"eighty":-2.322158,"marketCap":424616947},{"date":"2025-07-03","current":-2.577994,"twenty":-11.896022,"median":-2.691086,"eighty":-2.323707,"marketCap":419596845},{"date":"2025-07-11","current":-3.102331,"twenty":-8.929847,"median":-2.679496,"eighty":-2.324434,"marketCap":504938576},{"date":"2025-07-18","current":-3.387633,"twenty":-8.364044,"median":-2.699206,"eighty":-2.336288,"marketCap":551374518},{"date":"2025-07-25","current":-4.194702,"twenty":-6.676265,"median":-2.718649,"eighty":-2.349239,"marketCap":682733850},{"date":"2025-08-01","current":-4.037914,"twenty":-6.187126,"median":-2.829882,"eighty":-2.35573,"marketCap":657214999},{"date":"2025-08-08","current":-3.804019,"twenty":-6.06727,"median":-2.865865,"eighty":-2.35573,"marketCap":619145893},{"date":"2025-08-15","current":-3.987237,"twenty":-5.542498,"median":-2.90956,"eighty":-2.36209,"marketCap":705768845},{"date":"2025-08-22","current":-4.02768,"twenty":-4.889717,"median":-2.928692,"eighty":-2.362211,"marketCap":712927599},{"date":"2025-08-29","current":-3.868286,"twenty":-4.698498,"median":-2.950685,"eighty":-2.372371,"marketCap":684713689},{"date":"2025-09-05","current":-4.039575,"twenty":-4.396216,"median":-2.982091,"eighty":-2.374493,"marketCap":715033114},{"date":"2025-09-12","current":-4.798483,"twenty":-4.881439,"median":-2.99503,"eighty":-2.389351,"marketCap":849365013},{"date":"2025-09-19","current":-4.629572,"twenty":-4.881439,"median":-3.063777,"eighty":-2.399463,"marketCap":819466690},{"date":"2025-09-26","current":-4.429735,"twenty":-4.835595,"median":-3.074895,"eighty":-2.402603,"marketCap":784094028},{"date":"2025-10-03","current":-4.984046,"twenty":-4.911724,"median":-3.083269,"eighty":-2.409912,"marketCap":882211057},{"date":"2025-10-10","current":-6.604159,"twenty":-5.180553,"median":-3.135974,"eighty":-2.413574,"marketCap":1168982288},{"date":"2025-10-17","current":-5.759607,"twenty":-5.320916,"median":-3.162575,"eighty":-2.420654,"marketCap":1019490677},{"date":"2025-10-24","current":-5.949928,"twenty":-5.76722,"median":-3.174048,"eighty":-2.42495,"marketCap":1053178928},{"date":"2025-10-31","current":-9.035303,"twenty":-6.083769,"median":-3.188498,"eighty":-2.432369,"marketCap":1599311910},{"date":"2025-11-07","current":-9.81546,"twenty":-6.198298,"median":-3.245204,"eighty":-2.444339,"marketCap":1737405107},{"date":"2025-11-14","current":-10.08009,"twenty":-6.457611,"median":-3.282468,"eighty":-2.446909,"marketCap":1914199059},{"date":"2025-11-21","current":-9.848299,"twenty":-7.258864,"median":-3.371139,"eighty":-2.451734,"marketCap":1870182143},{"date":"2025-11-28","current":-10.976161,"twenty":-8.972029,"median":-3.394997,"eighty":-2.453948,"marketCap":2084362015},{"date":"2025-12-05","current":-10.772637,"twenty":-9.459248,"median":-3.515773,"eighty":-2.459247,"marketCap":2045713016},{"date":"2025-12-12","current":-11.366249,"twenty":-9.83041,"median":-3.643766,"eighty":-2.466418,"marketCap":2158439264},{"date":"2025-12-19","current":-9.913314,"twenty":-9.980024,"median":-3.678075,"eighty":-2.469682,"marketCap":1882528351},{"date":"2025-12-26","current":-12.202958,"twenty":-10.134363,"median":-3.729636,"eighty":-2.472265,"marketCap":2317329596},{"date":"2026-01-02","current":-10.263827,"twenty":-10.232168,"median":-3.760324,"eighty":-2.476253,"marketCap":1949090517},{"date":"2026-01-09","current":-4.638651,"twenty":-10.207521,"median":-3.79333,"eighty":-2.479511,"marketCap":880875114},{"date":"2026-01-16","current":-5.633657,"twenty":-10.159019,"median":-3.831007,"eighty":-2.483289,"marketCap":1069825778},{"date":"2026-01-23","current":-5.766513,"twenty":-10.142278,"median":-3.88256,"eighty":-2.488034,"marketCap":1095054986},{"date":"2026-01-30","current":-5.902195,"twenty":-10.122491,"median":-3.950232,"eighty":-2.490604,"marketCap":1120820986},{"date":"2026-02-06","current":-5.938943,"twenty":-10.119664,"median":-3.975342,"eighty":-2.498305,"marketCap":1127799277},{"date":"2026-02-13","current":-7.380571,"twenty":-10.08009,"median":-4.008147,"eighty":-2.503456,"marketCap":1401563024},{"date":"2026-02-20","current":-7.637803,"twenty":-9.946669,"median":-4.026371,"eighty":-2.50452,"marketCap":1450411065},{"date":"2026-02-27","current":-7.451239,"twenty":-9.897484,"median":-4.035344,"eighty":-2.514003,"marketCap":1414982815},{"date":"2026-03-06","current":-7.140299,"twenty":-9.857345,"median":-4.041954,"eighty":-2.520051,"marketCap":1355935733},{"date":"2026-03-13","current":-6.925469,"twenty":-9.824447,"median":-4.068124,"eighty":-2.528764,"marketCap":1315139567},{"date":"2026-03-20","current":-3.549457,"twenty":-9.816065,"median":-4.041954,"eighty":-2.535893,"marketCap":1340761298},{"date":"2026-03-26","current":-3.370238,"twenty":-9.777499,"median":-4.036629,"eighty":-2.541078,"marketCap":1273063466}],"updateTime":1774666464031},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"ZBIO\",pageSize:20,pageCount:1,lang_content:\"cn\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2622876581","title":"BUZZ--美國股票走勢-Entergy 公司、IDEX 公司、廣達服務公司","url":"https://stock-news.laohu8.com/highlight/detail?id=2622876581","media":"路透中文","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2622876581?lang=zh_tw&edition=fundamental","pubTime":"2026-03-27 23:49","pubTimestamp":1774626562,"startTime":"0","endTime":"0","summary":".N美国东部时间11:30，道琼斯工业平均指数.DJI下跌0.71%，报45,632.17点。标普500指数.SPX下跌0.67%，报6,433.77点；纳斯达克综合指数.IXIC下跌1.07%，报21,179.27点。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"37684715aaf54a73b9fe52ee56a263cc","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260327:nL4S40F19K:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["ARTL","GGLL","HKIT","CRWD","LTRN","SHPH","VATE","SST","CCL.UK","FIAT","PANW","CONI","FPS","DIS","FTNT","DOV","BKSY","EMR","ANAB","02026","ICOI","CONX","AGX","DDOG","ETN","RCKT","DISO","SAIL","BTGO","DTCX","ITRM","PWR","WIX","AME","VOR","PHAT","TWO","IEX","ETR","FCHL","CCL","GGLS","PH","ZBIO","ADMA","HON"],"gpt_icon":1},{"id":"2622765898","title":"BUZZ--美國股票走勢-Entergy 公司、IDEX 公司、廣達服務公司","url":"https://stock-news.laohu8.com/highlight/detail?id=2622765898","media":"路透中文","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2622765898?lang=zh_tw&edition=fundamental","pubTime":"2026-03-27 23:49","pubTimestamp":1774626562,"startTime":"0","endTime":"0","summary":".N美国东部时间11:30，道琼斯工业平均指数.DJI下跌0.71%，报45,632.17点。标普500指数.SPX下跌0.67%，报6,433.77点；纳斯达克综合指数.IXIC下跌1.07%，报21,179.27点。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"37684715aaf54a73b9fe52ee56a263cc","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260327:nL4T40F19K:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02026","ANAB","RCKT","PANW","TWO","CRWD","DOV","BKSY","CONY","PH","FTNT","DIS","DTCX","FCHL","AME","PANG","COIW","ITRM","WIX","FPS","VATE","ETR","BTGO","LTRN","SHPH","COIG","GOOW","HON","ADMA","SAIL","VOR","IEX","PHAT","HKIT","PWR","EMR","ETN","SST","AGX","ZBIO","CCL","CCL.UK","ARTL","PALD","DDOG"],"gpt_icon":1},{"id":"1123848176","title":"Zenas BioPharma完成3億美元融資：發行可轉債與普通股，加速自免藥物開發","url":"https://stock-news.laohu8.com/highlight/detail?id=1123848176","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1123848176?lang=zh_tw&edition=fundamental","pubTime":"2026-03-27 12:13","pubTimestamp":1774584809,"startTime":"0","endTime":"0","summary":"Zenas BioPharma完成3亿美元融资：发行可转债与普通股，加速自免药物开发生物制药公司Zenas BioPharma宣布，已完成同时公开发行2032年到期的2.50%可转换优先票据和普通股，募集资金总额达3亿美元。公司计划将净收益主要用于推进obexelimab的全球三期临床试验，以及其他早期自免候选药物的研究。自免疾病赛道竞争加剧Zenas BioPharma专注于开发针对自身免疫性疾病的创新疗法。此次融资将为Zenas提供充足的资金跑道，支持其关键临床试验的推进。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["ZBIO","BK4139"],"gpt_icon":0},{"id":"2622089145","title":"BUZZ-Zenas 生物製藥公司因發行可轉換債券和股票而下跌","url":"https://stock-news.laohu8.com/highlight/detail?id=2622089145","media":"路透中文","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2622089145?lang=zh_tw&edition=fundamental","pubTime":"2026-03-27 05:16","pubTimestamp":1774559764,"startTime":"0","endTime":"0","summary":"3月26日 - ** Zenas BioPharma <ZBIO.O>股价在筹资消息公布后盘后下跌9.8%，至20美元。** ZBIO公司股票周四收盘下跌0.1%，报22.16美元。在 2025 年股价飙升四倍多之后，今年以来股价下跌 39%。由于自动化翻译可能有误，或未能包含所需语境，路透不保证自动化翻译文本的准确性，仅是为了便利读者而提供自动化翻译。对于因为使用自动化翻译功能而造成的任何损害或损失，路透不承担任何责任。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"37684715aaf54a73b9fe52ee56a263cc","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260326:nL4T40E1SJ:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4127","BK4207","LU1791807156.HKD","LU2360032135.SGD","LU0106831901.USD","BK4559","LU1201861249.SGD","EVR","IE00BSNM7G36.USD","LU2417539215.USD","LU1366192091.USD","LU2125154935.USD","BK4566","LU1244550221.USD","LU0052756011.USD","LU0648001328.SGD","BK4534","LU0130102774.USD","BK4139","LU1506573853.SGD","LU2456880835.USD","BK4504","LU0314106906.USD","BK4588","LU0477156953.USD","LU1162221912.USD","LU0072461881.USD","LU2236285917.USD","LU0320765646.SGD","LU1244550577.SGD","LU0098860793.USD","LU2462157665.USD","LU1244550494.USD","LU0310800965.SGD","LU0128525689.USD","LU0170899867.USD","BK4585","LU0162691827.USD","LU1668664300.SGD","LU2125154778.USD","ZBIO","LU0130517989.USD","LU0980610538.SGD","LU1267930227.SGD"],"gpt_icon":0},{"id":"1133548955","title":"Zenas BioPharma Inc. 融資收益將用於支持Obexelimab美國上市、管線推進及一般企業用途","url":"https://stock-news.laohu8.com/highlight/detail?id=1133548955","media":"美股速递","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1133548955?lang=zh_tw&edition=fundamental","pubTime":"2026-03-27 04:03","pubTimestamp":1774555391,"startTime":"0","endTime":"0","summary":"Zenas BioPharma Inc. 近日宣布，其通过融资所获收益将专项用于支持其核心产品Obexelimab在美国市场的商业化上市准备工作。此外，部分资金也将用于推动公司研发管线的进一步拓展，以及其他一般企业运营目的。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["ZBIO","BK4139"],"gpt_icon":0},{"id":"1148820224","title":"Zenas BioPharma宣佈擬同步公開發行2032年到期可轉換優先票據及普通股","url":"https://stock-news.laohu8.com/highlight/detail?id=1148820224","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1148820224?lang=zh_tw&edition=fundamental","pubTime":"2026-03-27 04:02","pubTimestamp":1774555361,"startTime":"0","endTime":"0","summary":"Zenas BioPharma Inc.披露了同步进行两项公开募资的计划：发行2032年到期的可转换优先票据，以及公司普通股。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["ZBIO","BK4139"],"gpt_icon":0},{"id":"1126645156","title":"Zenas BioPharma 公布2025年第四季度及全年財務業績並更新公司進展","url":"https://stock-news.laohu8.com/highlight/detail?id=1126645156","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1126645156?lang=zh_tw&edition=fundamental","pubTime":"2026-03-16 19:01","pubTimestamp":1773658872,"startTime":"0","endTime":"0","summary":"Zenas BioPharma Inc. (ZBIO) 已正式发布其2025年第四季度及全年的财务报告。此次公告同时包含了公司最新的运营动态与发展规划。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","ZBIO"],"gpt_icon":0},{"id":"1101729423","title":"Zenas BioPharma公布Obexelimab治療複發性多發性硬化症的2期Moonstone試驗結果，將於2026年Actrims論壇進行突破性平台展示","url":"https://stock-news.laohu8.com/highlight/detail?id=1101729423","media":"美股速递","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1101729423?lang=zh_tw&edition=fundamental","pubTime":"2026-02-09 20:07","pubTimestamp":1770638833,"startTime":"0","endTime":"0","summary":"Zenas BioPharma（纳斯达克代码：ZBIO）近日宣布，其针对复发性多发性硬化症研发的药物Obexelimab，在2期Moonstone临床试验中取得重要成果。这些突破性数据将于2026年在美国Actrims论坛上，以“最新突破性平台展示”的形式进行公布。\n此次公布标志着Obexelimab在治疗自身免疫性疾病领域迈出关键一步，也为全球多发性硬化症患者带来了新的希望。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["ZBIO","BK4139"],"gpt_icon":0},{"id":"2609651785","title":"Zenas Biopharma, Inc.盤中異動 股價大漲5.14%","url":"https://stock-news.laohu8.com/highlight/detail?id=2609651785","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2609651785?lang=zh_tw&edition=fundamental","pubTime":"2026-02-06 22:41","pubTimestamp":1770388865,"startTime":"0","endTime":"0","summary":"北京时间2026年02月06日22时41分，Zenas Biopharma, Inc.股票出现异动，股价急速上涨5.14%。Zenas Biopharma, Inc.股票所在的生物技术行业中，整体涨幅为1.04%。其相关个股中，Cingulate Inc C/Wts 10/12/2026 、Klotho Neurosciences Inc C/Wts 21/06/2029 、Liminatus Pharma Inc C/Wts 30/04/2030 涨幅较大，Clearmind Medicine Inc.、Liminatus Pharma, Inc.、Aim Immunotech Inc.较为活跃，换手率分别为418.51%、18.28%、15.33%，振幅较大的相关个股有Estrella Immunopharma Inc C/Wts 29/09/2028、Cingulate Inc C/Wts 10/12/2026 、Liminatus Pharma Inc C/Wts 30/04/2030 ，振幅分别为47.83%、21.54%、18.03%。Zenas Biopharma, Inc.公司简介：泽纳仕生物有限公司是一家处于临床阶段的生物制药公司。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260206224106a6dc117c&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260206224106a6dc117c&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["ZBIO","BK4139"],"gpt_icon":0},{"id":"2608539373","title":"Zenas Biopharma, Inc.盤中異動 股價大漲5.12%報19.08美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2608539373","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2608539373?lang=zh_tw&edition=fundamental","pubTime":"2026-02-03 23:05","pubTimestamp":1770131141,"startTime":"0","endTime":"0","summary":"北京时间2026年02月03日23时05分，Zenas Biopharma, Inc.股票出现异动，股价大幅上涨5.12%。截至发稿，该股报19.08美元/股，成交量8.8393万股，换手率0.16%，振幅5.45%。Zenas Biopharma, Inc.股票所在的生物技术行业中，整体涨幅为0.86%。Zenas Biopharma, Inc.公司简介：泽纳仕生物有限公司是一家处于临床阶段的生物制药公司。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2026020323054197a4b3ae&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2026020323054197a4b3ae&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK4139","ZBIO"],"gpt_icon":0},{"id":"2605455713","title":"Zenas Biopharma, Inc.盤中異動 早盤急速下挫5.12%","url":"https://stock-news.laohu8.com/highlight/detail?id=2605455713","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2605455713?lang=zh_tw&edition=fundamental","pubTime":"2026-01-22 00:21","pubTimestamp":1769012470,"startTime":"0","endTime":"0","summary":"北京时间2026年01月22日00时21分，Zenas Biopharma, Inc.股票出现波动，股价快速跳水5.12%。Zenas Biopharma, Inc.股票所在的生物技术行业中，整体涨幅为1.01%。其相关个股中，Lisata Therapeutics, Inc.、Moolec Science Sa、Moolec Science Sa C/Wts 30/01/2028涨幅较大，Aditxt, Inc.、Revelation Biosciences, Inc.、Lisata Therapeutics, Inc.较为活跃，换手率分别为1204.36%、81.52%、46.59%，振幅较大的相关个股有Moolec Science Sa C/Wts 30/01/2028、Jasper Therapeutics Inc C/Wts 24/09/2026 、Io Biotech, Inc.，振幅分别为71.60%、68.10%、45.77%。Zenas Biopharma, Inc.公司简介：泽纳仕生物有限公司是一家处于临床阶段的生物制药公司。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260122002110a4465546&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260122002110a4465546&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK4139","ZBIO"],"gpt_icon":0},{"id":"2601043864","title":"美國研究綜述-不倫瑞克、派克-漢尼汾、XPLR 基礎設施","url":"https://stock-news.laohu8.com/highlight/detail?id=2601043864","media":"路透中文","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2601043864?lang=zh_tw&edition=fundamental","pubTime":"2026-01-06 15:54","pubTimestamp":1767686040,"startTime":"0","endTime":"0","summary":"美国研究综述-不伦瑞克、派克-汉尼汾、XPLR 基础设施路透1月6日 - 华尔街证券分析师周二修订了对几家美国上市公司的评级和目标价，其中包括 Brunswick、Parker-Hannifin 和 XPLR Infrastructure。股票条目按字母顺序排列。由于自动化翻译可能有误，或未能包含所需语境，路透不保证自动化翻译文本的准确性，仅是为了便利读者而提供自动化翻译。对于因为使用自动化翻译功能而造成的任何损害或损失，路透不承担任何责任。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260106:nL4S3Y70G0:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4141","MAN","RJF","LU1046421795.USD","ROL","LU0175139822.USD","MCHP","IBKR","WLTH","BK4547","LU1121112475.USD","PH","IE00B7SZL793.SGD","AGIO","SCHW","LU0300736062.USD","VRSN","LU2237443465.HKD","XIFR","DC","LPLA","LU1548497426.USD","LU2360107671.USD","BC","HUBG","BK4137","LU0211331839.USD","LU0353189763.USD","TRV","LU0528227936.USD","ZBIO","LU0566484027.USD","SNDR","BBBY","LU0348723411.USD","BK4561","BK4605","SG9999014013.SGD","CTAS","LU0278409577.USD","LU1732800096.USD","LU1983260115.SGD","CWST","ALB","BK4146","EXPD"],"gpt_icon":1},{"id":"1195864515","title":"Zenas BioPharma股價因免疫疾病藥物後期數據不佳而跌至逾四個月低點，日內跌幅達55%","url":"https://stock-news.laohu8.com/highlight/detail?id=1195864515","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1195864515?lang=zh_tw&edition=fundamental","pubTime":"2026-01-05 23:30","pubTimestamp":1767627041,"startTime":"0","endTime":"0","summary":"Zenas BioPharma Inc. (ZBIO) 股价近日遭遇重挫，创下逾四个月以来的新低。此次股价大幅下跌的主要原因是其免疫疾病药物的后期临床试验数据未达市场预期，导致投资者信心受挫。截至最新交易时段，该公司股价当日跌幅高达55%，反映出市场对其药物研发前景的担忧。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-2","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["ZBIO","BK4139"],"gpt_icon":0},{"id":"2601810808","title":"Zenas 生物製藥公司的免疫紊亂藥物在後期試驗中達到主要目標","url":"https://stock-news.laohu8.com/highlight/detail?id=2601810808","media":"路透中文","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2601810808?lang=zh_tw&edition=fundamental","pubTime":"2026-01-05 21:25","pubTimestamp":1767619521,"startTime":"0","endTime":"0","summary":"路透1月5日 - Zenas生物制药公司ZBIO.O周一称，在一项针对罕见的免疫系统相关疾病患者的后期研究中，该公司的实验性药物降低了疾病复发的风险。该公司说，Zenas 公司的药物在其他四个次要目标上的表现也优于安慰剂，包括实现完全缓解的患者比例。Zenas 计划今年 寻求 美国和欧洲监管机构的批准 。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260105:nL4T3Y60VZ:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4588","BMY","LU0096364046.USD","LU0985481810.HKD","BK4585","ZBIO","LU0061475181.USD","LU1868836591.USD","BK4559","LU1093756325.SGD","LU1291159041.SGD","LU1868837300.USD","BK4534","BK4532","LU0321505868.SGD","LU1057294990.SGD","LU1718418525.SGD","LU1571399168.USD","IE00B4R5TH58.HKD","BK4139","IE00B2B36J28.USD","LU1868837136.USD","LU0122379950.USD","LU2089984988.USD","LU1585245621.USD","LU0237698245.USD","LU0289739699.SGD","BK4566","LU1989771016.USD","IE00BSNM7G36.USD","LU0267386448.USD","IE00BFTCPJ56.SGD","IE00BJJMRZ35.SGD","LU0306807586.USD","LU2112291526.USD","LU2242652126.USD","LU0868494617.USD","LU1670711123.USD","LU1868836914.USD","BK4581","LU1868836757.USD","IE0002141913.USD","LU2242646821.SGD","AMGN","LU0320765992.SGD","LU1670710588.SGD","LU0889565916.HKD","LU0225771236.USD","SG9999001440.SGD"],"gpt_icon":0},{"id":"1165846039","title":"Zenas BioPharma公布Obexelimab治療IgG4相關疾病3期INDIGO註冊試驗積極結果","url":"https://stock-news.laohu8.com/highlight/detail?id=1165846039","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1165846039?lang=zh_tw&edition=fundamental","pubTime":"2026-01-05 20:06","pubTimestamp":1767614762,"startTime":"0","endTime":"0","summary":"Zenas BioPharma宣布，其药物Obexelimab在针对免疫球蛋白G4相关疾病（IgG4-RD）的3期INDIGO注册试验中取得了积极成果。该试验达到了主要终点，显示出显著疗效和良好安全性，为后续监管申报奠定了坚实基础。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","ZBIO"],"gpt_icon":0},{"id":"1133394639","title":"InnoCare Pharma宣佈Orelabrutinib（Btk抑制劑）在系統性紅斑狼瘡的2B期研究中實現主要終點","url":"https://stock-news.laohu8.com/highlight/detail?id=1133394639","media":"美股速递","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1133394639?lang=zh_tw&edition=fundamental","pubTime":"2025-12-15 20:07","pubTimestamp":1765800457,"startTime":"0","endTime":"0","summary":"InnoCare Pharma宣布在针对系统性红斑狼疮的Orelabrutinib（Btk抑制剂）2B期研究中实现了主要终点。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","ZBIO"],"gpt_icon":0},{"id":"1142056905","title":"Zenas BioPharma：Obexelimab三期Indigo試驗在免疫球蛋白G4相關疾病（IgG4-RD）中的初步結果預計將在年末公布","url":"https://stock-news.laohu8.com/highlight/detail?id=1142056905","media":"美股速递","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1142056905?lang=zh_tw&edition=fundamental","pubTime":"2025-11-12 20:13","pubTimestamp":1762949593,"startTime":"0","endTime":"0","summary":"Zenas BioPharma：Obexelimab三期Indigo试验在免疫球蛋白G4相关疾病（IgG4-RD）中的初步结果预计将在年末公布","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","ZBIO"],"gpt_icon":0},{"id":"1122038621","title":"Zenas Biopharma公布Obexelimab在複發性多發性硬化症II期Moonstone試驗中取得積極結果","url":"https://stock-news.laohu8.com/highlight/detail?id=1122038621","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1122038621?lang=zh_tw&edition=fundamental","pubTime":"2025-10-27 19:08","pubTimestamp":1761563296,"startTime":"0","endTime":"0","summary":"Zenas Biopharma公布Obexelimab在复发性多发性硬化症II期Moonstone试验中取得积极结果","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","ZBIO"],"gpt_icon":0},{"id":"1165438252","title":"Zenas Biopharma預計將在2026年第一季度啓動Orelabrutinib針對繼發漸進性多發性硬化症患者的全球三級臨床試驗","url":"https://stock-news.laohu8.com/highlight/detail?id=1165438252","media":"美股速递","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1165438252?lang=zh_tw&edition=fundamental","pubTime":"2025-10-27 19:08","pubTimestamp":1761563293,"startTime":"0","endTime":"0","summary":"Zenas Biopharma预计将在2026年第一季度启动Orelabrutinib针对继发渐进性多发性硬化症患者的全球三级临床试验。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","ZBIO"],"gpt_icon":0},{"id":"1122167777","title":"Zenas Biopharma向SEC申請最多出售630萬股普通股的架構籌資","url":"https://stock-news.laohu8.com/highlight/detail?id=1122167777","media":"美股速递","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1122167777?lang=zh_tw&edition=fundamental","pubTime":"2025-10-22 04:49","pubTimestamp":1761079748,"startTime":"0","endTime":"0","summary":"Zenas Biopharma向SEC申请最多出售630万股普通股，出售股东为卖方。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["ZBIO","BK4139"],"gpt_icon":0}],"pageSize":20,"totalPage":2,"pageCount":1,"totalSize":26,"code":"91000000","status":"200"}]}}